ClinicalTrials.gg
CompletedNCT02173704Updated Aug 25, 2020Results posted

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

A Phase 3 interventional study of Bexsero® and Routine vaccines in Meningococcal Disease and Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 2 sites in Taiwan. Open to participants aged 55 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-25.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
55 Days to 89 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.

Enrollment
13th of 21
225 · median 508
Started
2014
with 2 others
Phase 3
7 of 21
none open now
Registered
13th of 21
by date
Lead sponsor
6 of 21
GlaxoSmithKline

Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 13th largest by enrollment, is one of 3 that started in 2014, is one of 7 in phase 3, and was the 13th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 55 Days to 89 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing 4CMenB vaccine in Meningococcal Infections, or all of them as a file.
02

Study summary

Assess the safety and immunogenicity of a 3-dose schedule (at 2, 4, 6 months) of GSK Biologicals' Meningococcal B recombinant vaccine followed by a booster at 12 months when concomitantly administered with routine vaccines in healthy infants in Taiwan.

03

Conditions studied

  • Meningococcal Disease
  • Infections, Meningococcal

Keywords

  • Meningitis
  • Infants
  • Meningococcal B Recombinant Vaccine
04

Who can participate

Ages eligible
55 Days to 89 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. healthy 2-month old infants (55-89 days, inclusive), who were born after full term pregnancy with an estimated gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg;
  2. for whom a parent/legal guardian has given written after the nature of the study has been explained;
  3. available for all the visits scheduled in the study;
  4. in good health as determined by medical history, physical examination and clinical judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  1. History of any meningococcal vaccine administration;
  2. Prior vaccination with any Diphtheria, Tetanus, Pertussis (acellular or whole cell), Polio (either Inactivated or Oral), Haemophilus influenzae type b (Hib), Pneumococcal, MMR or varicella antigens;
  3. Previous ascertained or suspected disease caused by N. meningitidis;
  4. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis;
  5. History of severe allergic reaction after previous vaccinations or to any vaccine component;
  6. Significant acute or chronic infection within the previous 7 days or body temperature higher or equal to 38C degrees within the previous day;
  7. Antibiotics within 6 days prior to enrollment;
  8. Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, insulin dependent diabetes mellitus Type I, cardiac disease, hepatic disease, progressive neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, disease, infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition);
  9. Known or suspected impairment/alteration of the immune system, therapy, use of systemic or chronic use of inhaled high-potency corticosteroids since birth;
  10. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation;
  11. Receipt of, or intent to immunize with any other vaccine(s) (with the exception of rotavirus vaccine, influenza vaccine and second HepB vaccine), within 28 days prior and throughout the study period. Furthermore, subjects must have received HepB vaccine preferably at 0, 1 month of age, with the second dose at least 14 days prior to study vaccination. Influenza vaccine should be administered at least 14 days before or 14 days after study vaccination; Rotavirus vaccine may be administered during the study as per local practice.
  12. Participation in another clinical trial since birth or planned for during study;
  13. Family members and household members of research staff;
  14. Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Bexsero + Routine Group

    Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.

    Biological: Bexsero®

  • Active comparator
    Routine Group

    Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.

    Biological: Routine vaccines

Interventions

  • BiologicalBexsero®

    Four doses administered in the anterolateral area of the right or left thigh.

  • BiologicalRoutine vaccines

    Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Human Serum Bactericidal Activity (hSBA) Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B Strains

    Percentage of subjects with hSBA titer ≥ 1:5 at 1 month following the third vaccination (at 7 months of age) against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 when Bexsero® was given concomitantly with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®).

    Time frame: At Day 1 and at one month after the third vaccination (Day 152)

  2. Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Titer ≥ 1:4 Against Neisseria Meningitidis Serogroup B Strains

    Percentage of subjects with hSBA titer ≥ 1:4 at 1 month after third vaccination (at 7 months of age) against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 when Bexsero® was given concomitantly with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®).

    Time frame: At Day 1 and at one month after third vaccination (Day 152)

Secondary outcomes

  1. Percentage of Subjects With hSBA Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B, When Bexsero® Booster Was Given With Routine Vaccines (Priorix® + Varilrix® Vaccines)

    Percentage of subjects with hSBA titer ≥ 1:5 before booster vaccination and after booster vaccination when Bexsero® booster dose was given with routine vaccines (Priorix® + Varilrix® vaccine) as compared to when only routine vaccines were administered.

    Time frame: At Day 305 and Day 335

  2. hSBA Geometric Mean Titers (GMTs) Against Neisseria Meningitidis Serogroup B Indicator Strains, When Bexsero® Vaccine Was Given With Routine Vaccines

    hSBA GMTs against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 was evaluated at baseline (2 months of age, Day 1), 1 month after the third vaccination with Bexsero® with concomitant routine vaccines (Infanrix-IPV+Hib®, Prevenar-13®, Engerix®) (7 months of age, Day 152) or prior to the booster dose of Bexsero® with routine vaccines (Priorix®, Varilrix®) (12 months of age, Day 305) and 1 month after the booster dose (13 months of age, Day 335), as compared to when only routine vaccines were administered.

    Time frame: At Day 1, Day 152, Day 305 and Day 335

  3. hSBA Geometric Mean Ratios (GMRs) Against Neisseria Meningitidis Serogroup B Strains.

    GMRs of post-vaccination versus pre-vaccination of hSBA titer against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 were evaluated at one month after the third vaccination with Bexsero® vaccine and concomitant routine vaccines (Infanrix-IPV+Hib®, Prevenar-13® and Engerix®) (Day 152) compared to baseline (Day 1) or at one month after the booster dose of Bexsero® vaccine with routine vaccines (Priorix®, Varilrix®) (Day 335) compared to prior to the booster dose (Day 305).

    Time frame: At Day 1, Day 152, Day 305 and Day 335

  4. Percentages of Subjects With hSBA Titers ≥1:8 Against Neisseria Meningitidis Serogroup B, When Bexsero® Vaccine Was Given With Routine Vaccines

    Percentages of subjects with hSBA titers ≥1:8 against N.meningitidis serogroup B strains, at one month after concomitant administration of third primary dose of Bexsero® with routine vaccines \[Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®\] and at one month after concomitant administration of Bexsero® booster dose with routine vaccines \[Priorix® and Varilrix® vaccine\],as compared to when only routine vaccines were administered.

    Time frame: At Day 1,Day 152,Day 305, Day 335

  5. Number of Subjects Reporting Solicited Local Adverse Events (AEs) After Receiving Bexsero® Vaccine With Routine Vaccine or Routine Vaccines Alone, at 2, 4, 6 and 12 Months of Age.

    Number of subjects reporting solicited local AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B® at 2, 4 and 6 months of age and Priorix® and Varilrix® at 12 months of age)compared to when only routine vaccines were administered alone at 2,4,6 and 12 months. Solicited local symptoms assessed were Erythema, Induration, Swelling and Tenderness.

    Time frame: From day 1 (6 hours) to day 7 after each vaccination (1st, 2nd, 3rd and 4th vaccination)

  6. Number of Subjects Reporting Solicited Systemic Adverse Events (AEs) After Receiving Bexsero® Vaccine With Routine Vaccine or Routine Vaccines Alone, at 2, 4, 6 and 12 Months of Age.

    Number of subjects reporting solicited systemic AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B® at 2, 4 and 6 months of age and Priorix® and Varilrix® at 12 months of age) compared to when only routine vaccines were alone, at 2, 4, 6 and 12 months. Systemic solicited symptoms assessed were Change in Eating Habits, Diarrhea, Irritability, Persistent Crying, Rash, Sleepiness, Vomiting and Fever (body temperature ≥ 38.0 °C)

    Time frame: From day 1 (6 hours) to day 7 after each vaccination

  7. Number of Subjects Reporting Solicited Systemic AEs After Receiving Priorix® and Varilrix® Routine Vaccines (With and Without Bexsero® Vaccine) at 12 Months of Age.

    Number of subjects who reported solicited systemic AEs reported after the administration of Varilrix® and Priorix® vaccines (with and without Bexsero® vaccine) at 12 months of age. Solicited systemic AEs assessed were Rash, Lymphadenopathy and Fever. This analysis was conducted for a prolonged period of 28 Days following Varilrix® and Priorix® administration.

    Time frame: From Day 1 to Day 28 after vaccination

  8. Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination With Routine Vaccines

    Number of subjects reporting any unsolicited AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B® or Priorix® and Varilrix®) compared to when only routine vaccines were administered alone.

    Time frame: From day 1 to day 7 after each vaccination

  9. Number of Subjects Reporting Serious Adverse Events (SAEs), Medically Attended AEs (MAEs) and AEs Leading to Premature Withdrawal and Death and AEs Leading to Hospitalization.

    Number of subjects reporting SAEs, medically attended AEs and AEs leading to premature withdrawal from the study and leading to death and AEs leading to hospitalization following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix®) compared to when only routine vaccines were administered alone. SAEs assessed included medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Possibly or probably related SAE were SAEs assessed by the investigator as related to the vaccination. Medically attended AEs were events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason.

    Time frame: Throughout the study period (Day 1 to Day 335)

07

Results

Posted Jun 15, 2018

Participant flow

Subjects were recruited from 2 sites in Taiwan

Participant flow — Overall Study
MilestoneBexsero + Routine GroupRoutine Group
Started15075
Completed13771
Not completed134
Withdrew: Adverse event10
Withdrew: Lost to follow-up10
Withdrew: Other10
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject94

Outcome measures

PrimaryPercentage of Subjects With Human Serum Bactericidal Activity (hSBA) Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B Strains

Percentage of subjects with hSBA titer ≥ 1:5 at 1 month following the third vaccination (at 7 months of age) against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 when Bexsero® was given concomitantly with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®).

Time frame:
At Day 1 and at one month after the third vaccination (Day 152)
Reported as:
Number · Percentages of subjects
Percentage of Subjects With Human Serum Bactericidal Activity (hSBA) Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B Strains
Percentages of subjectsBexsero + Routine GroupRoutine Group
H44/76 strain [Day 1]0 (0.0 to 3.1)0 (0.0 to 6.1)
H44/76 strain [Day 152]100 (97.2 to 100)0 (0.0 to 5.4)
5/99 strain [Day 1]1 (0.02 to 4.4)1 (0.04 to 7.8)
5/99 strain [Day 152]100 (97.2 to 100)0 (0.0 to 5.1)
M10713 strain [Day 1]10 (4.9 to 17.6)19 (10 to 31.9)
M10713 strain [Day 152]59 (50.1 to 68.1)8 (2.5 to 17)
NZ98/254 strain [Day 1]0 (0.0 to 2.7)0 (0.0 to 5.1)
NZ98/254 strain [Day 152]79 (71.4 to 85.8)0 (0.0 to 5.1)
Statistical analysis
  • Bexsero + Routine Group vs Routine Group · Exact test of binomial proportion · Single binomial proportion: 100 · 95% CI 97.2 to 100
  • Bexsero + Routine Group vs Routine Group · Exact test of binomial proportion · Single binomial proportion: 79 · 95% CI 71.4 to 85.8
PrimaryPercentage of Subjects With Human Serum Bactericidal Assay (hSBA) Titer ≥ 1:4 Against Neisseria Meningitidis Serogroup B Strains

Percentage of subjects with hSBA titer ≥ 1:4 at 1 month after third vaccination (at 7 months of age) against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 when Bexsero® was given concomitantly with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®).

Time frame:
At Day 1 and at one month after third vaccination (Day 152)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Titer ≥ 1:4 Against Neisseria Meningitidis Serogroup B Strains
Percentage of subjectsBexsero + Routine GroupRoutine Group
H44/76 strain [Day 1]0 (0.0 to 3.1)0 (0.0 to 6.1)
H44/76 strain [Day 152]100 (97.2 to 100)0 (0.0 to 5.4)
5/99 strain [Day 1]1 (0.02 to 4.4)1 (0.04 to 7.8)
5/99 strain [Day 152]100 (97.2 to 100)0 (0.0 to 5.1)
M10713 strain [Day 1]11 (5.6 to 18.8)25 (14.1 to 37.8)
M10713 strain [Day 152]71 (61.9 to 78.6)8 (2.5 to 17.0)
NZ98/254 strain [Day 1]0 (0.0 to 2.7)0 (0.0 to 5.1)
NZ98/254 strain [Day 152]87 (80.6 to 92.5)0 (0.0 to 5.1)
SecondaryPercentage of Subjects With hSBA Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B, When Bexsero® Booster Was Given With Routine Vaccines (Priorix® + Varilrix® Vaccines)

Percentage of subjects with hSBA titer ≥ 1:5 before booster vaccination and after booster vaccination when Bexsero® booster dose was given with routine vaccines (Priorix® + Varilrix® vaccine) as compared to when only routine vaccines were administered.

Time frame:
At Day 305 and Day 335
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B, When Bexsero® Booster Was Given With Routine Vaccines (Priorix® + Varilrix® Vaccines)
Percentage of subjectsBexsero + Routine GroupRoutine Group
H44/76 strain [Day 305]81 (73.3 to 87.8)2 (0.04 to 8.4)
H44/76 strain [Day 335]99 (95.7 to 99.98)2 (0.04 to 8.4)
5/99 strain [Day 305]99 (94.8 to 99.82)1 (0.04 to 7.7)
5/99 strain [Day 335]99 (94.7 to 99.82)0 (0 to 5.1)
M10713 strain [Day 305]22 (14.8 to 29.6)11 (4.4 to 20.9)
M10713 strain [Day 335]92 (86.3 to 96.2)13 (6.1 to 23.3)
NZ98/254 strain [Day 305]17 (11 to 24.3)1 (0.04 to 7.7)
NZ98/254 strain [Day 335]94 (88.7 to 97.4)0 (0 to 5.1)
Statistical analysis
  • Bexsero + Routine Group vs Routine Group · Exact test of binomial proportion · Single binomial proportion: 99 · 95% CI 95.7 to 99.98
  • Bexsero + Routine Group vs Routine Group · Exact test for binomial proportion · Single binomial proportion: 99 · 95% CI 94.7 to 99.82
  • Bexsero + Routine Group vs Routine Group · Exact test for binomial proportions · Single binomial proportion: 94 · 95% CI 88.7 to 97.4
SecondaryhSBA Geometric Mean Titers (GMTs) Against Neisseria Meningitidis Serogroup B Indicator Strains, When Bexsero® Vaccine Was Given With Routine Vaccines

hSBA GMTs against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 was evaluated at baseline (2 months of age, Day 1), 1 month after the third vaccination with Bexsero® with concomitant routine vaccines (Infanrix-IPV+Hib®, Prevenar-13®, Engerix®) (7 months of age, Day 152) or prior to the booster dose of Bexsero® with routine vaccines (Priorix®, Varilrix®) (12 months of age, Day 305) and 1 month after the booster dose (13 months of age, Day 335), as compared to when only routine vaccines were administered.

Time frame:
At Day 1, Day 152, Day 305 and Day 335
Reported as:
Geometric mean · Titer
hSBA Geometric Mean Titers (GMTs) Against Neisseria Meningitidis Serogroup B Indicator Strains, When Bexsero® Vaccine Was Given With Routine Vaccines
TiterBexsero + Routine GroupRoutine Group
H44/76 strain [Day 1]1.01 (0.99 to 1.02)1.02 (0.98 to 1.05)
H44/76 strain [Day 152]72 (64 to 81)1.01 (0.99 to 1.03)
H44/76 strain [Day 305]11 (9.27 to 13)1.26 (1.06 to 1.5)
H44/76 strain [Day 335]157 (131 to 188)1.1 (1.01 to 1.19)
5/99 strain [Day 1]1.08 (0.98 to 1.18)1.03 (0.98 to 1.08)
5/99 strain [Day 152]963 (864 to 1073)1 (1 to 1)
5/99 strain [Day 305]205 (174 to 242)1.1 (0.91 to 1.33)
5/99 strain [Day 335]2315 (1893 to 2832)1 (1 to 1)
M10713 strain [Day 1]1.36 (1.2 to 1.54)1.75 (1.37 to 2.24)
M10713 strain [Day 152]8.41 (6.63 to 11)1.25 (1.08 to 1.46)
M10713 strain [Day 305]2.18 (1.81 to 2.63)1.6 (1.34 to 1.91)
M10713 strain [Day 335]17 (14 to 20)1.58 (1.33 to 1.89)
NZ98/254 strain [Day 1]1.01 (0.99 to 1.02)1 (1 to 1)
NZ98/254 strain [Day 152]9.2 (7.82 to 11)1.02 (0.98 to 1.05)
NZ98/254 strain [Day 305]1.91 (1.63 to 2.25)1.04 (0.98 to 1.1)
NZ98/254 strain [Day 335]26 (21 to 31)1 (1 to 1)
SecondaryhSBA Geometric Mean Ratios (GMRs) Against Neisseria Meningitidis Serogroup B Strains.

GMRs of post-vaccination versus pre-vaccination of hSBA titer against the indicator strains H44/76, 5/99, NZ98/254 and strain M10713 were evaluated at one month after the third vaccination with Bexsero® vaccine and concomitant routine vaccines (Infanrix-IPV+Hib®, Prevenar-13® and Engerix®) (Day 152) compared to baseline (Day 1) or at one month after the booster dose of Bexsero® vaccine with routine vaccines (Priorix®, Varilrix®) (Day 335) compared to prior to the booster dose (Day 305).

Time frame:
At Day 1, Day 152, Day 305 and Day 335
Reported as:
Geometric mean · Ratio
hSBA Geometric Mean Ratios (GMRs) Against Neisseria Meningitidis Serogroup B Strains.
RatioBexsero + Routine GroupRoutine Group
H44/76 strain [Day 152/Day 1]71 (63 to 80)0.99 (0.95 to 1.04)
H44/76 strain [Day 335/Day 305]155 (127 to 188)1.07 (0.97 to 1.19)
5/99 strain [Day 152/Day 1]875 (752 to 1019)0.97 (0.93 to 1.03)
5/99 strain [Day 335/Day 305]2110 (1674 to 2659)0.97 (0.93 to 1.03)
M10713 strain [Day 152/Day 1]5.69 (4.25 to 7.61)0.68 (0.54 to 0.85)
M10713 strain [Day 335/Day 305]12 (8.99 to 15)0.91 (0.68 to 1.21)
NZ98/254 strain [Day 152/Day 1]9.18 (7.79 to 11)1.02 (0.98 to 1.05)
NZ98/254 strain [Day 335/Day 305]25 (21 to 31)1 (1 to 1)
SecondaryPercentages of Subjects With hSBA Titers ≥1:8 Against Neisseria Meningitidis Serogroup B, When Bexsero® Vaccine Was Given With Routine Vaccines

Percentages of subjects with hSBA titers ≥1:8 against N.meningitidis serogroup B strains, at one month after concomitant administration of third primary dose of Bexsero® with routine vaccines \[Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B®\] and at one month after concomitant administration of Bexsero® booster dose with routine vaccines \[Priorix® and Varilrix® vaccine\],as compared to when only routine vaccines were administered.

Time frame:
At Day 1,Day 152,Day 305, Day 335
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥1:8 Against Neisseria Meningitidis Serogroup B, When Bexsero® Vaccine Was Given With Routine Vaccines
Percentages of subjectsBexsero + Routine GroupRoutine Group
H44/76 strain (Day 1)0 (0.0 to 2.8)0 (0.0 to 5.5)
H44/76 strain (Day 152)100 (97.2 to 100)0 (0.0 to 5.4)
H44/76 strain (Day 305)66 (56.8 to 74.2)2 (0.04 to 8.4)
H44/76 strain (Day 335)99 (95.7 to 99.98)0 (0.0 to 5.6)
5/99 strain (Day 1)1 (0.02 to 3.9)0 (0.0 to 5.0)
5/99 strain (Day 152)100 (97.2 to 100)0 (0.0 to 5.1)
5/99 strain (Day 305)99 (94.8 to 99.82)1 (0.04 to 7.7)
5/99 strain (Day 335)99 (94.7 to 99.82)0 (0.0 to 5.1)
M10713 strain (Day 1)3 (0.9 to 8.2)8 (2.6 to 17.3)
M10713 strain (Day 152)49 (39.7 to 58.0)5 (1.0 to 12.9)
M10713 strain (Day 305)15 (9.7 to 22.8)3 (0.37 to 10.7)
M10713 strain (Day 335)77 (68.7 to 83.9)6 (1.6 to 14.2)
NZ98/254 strain (Day 1)0 (0.0 to 2.5)0 (0.0 to 4.9)
NZ98/254 strain (Day 152)59 (49.7 to 66.9)0 (0.0 to 5.1)
NZ98/254 strain (Day 305)9 (4.6 to 14.9)0 (0.0 to 5.1)
NZ98/254 strain (Day 335)86 (79.0 to 91.4)0 (0.0 to 5.1)
SecondaryNumber of Subjects Reporting Solicited Local Adverse Events (AEs) After Receiving Bexsero® Vaccine With Routine Vaccine or Routine Vaccines Alone, at 2, 4, 6 and 12 Months of Age.

Number of subjects reporting solicited local AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B® at 2, 4 and 6 months of age and Priorix® and Varilrix® at 12 months of age)compared to when only routine vaccines were administered alone at 2,4,6 and 12 months. Solicited local symptoms assessed were Erythema, Induration, Swelling and Tenderness.

Time frame:
From day 1 (6 hours) to day 7 after each vaccination (1st, 2nd, 3rd and 4th vaccination)
Reported as:
Number · Number of participants
Number of Subjects Reporting Solicited Local Adverse Events (AEs) After Receiving Bexsero® Vaccine With Routine Vaccine or Routine Vaccines Alone, at 2, 4, 6 and 12 Months of Age.
Number of participantsBexsero + Routine GroupRoutine Group
Any Erythema (1st Bexsero®)54—
Grade 3 Erythema (1st Bexsero®)0—
Any Swelling (1st Bexsero®)34—
Grade 3 Swelling (1st Bexsero®)0—
Any Induration (1st Bexsero®)63—
Grade 3 Induration (1st Bexsero®)0—
Any Tenderness (1st Bexsero®)75—
Grade 3 Tenderness (1st Bexsero®)8—
Any Erythema (1st Infanrix-IPV + Hib®)263
Grade 3 Erythema(1st Infanrix-IPV+Hib®)00
Any Swelling (1st Infanrix-IPV + Hib®)153
Grade 3 Swelling(1st Infanrix-IPV+Hib®)00
Any Tenderness (1st Infanrix-IPV + Hib®)4512
Grade 3Tenderness(1st Infanrix-IPV+Hib®)20
Any Induration(1st Infanrix-IPV + Hib®)2311
Grade 3Induration(1st Infanrix-IPV+Hib®)00
Any Erythema (1st Prevenar-13®)269
Grade 3 Erythema (1st Prevenar-13®)00
Any Induration (1st Prevenar-13®)2915
Grade 3 Induration (1st Prevenar-13®)00
Any Swelling (1st Prevenar-13®)114
Grade 3 Swelling (1st Prevenar-13®)00
Any Tenderness (1st Prevenar-13®)5012
Grade 3 Tenderness (1st Prevenar-13®)30
Any Erythema (2nd Bexsero®)59—
Grade 3 Erythema (2nd Bexsero®)0—
Any Swelling (2nd Bexsero®)35—
Grade 3 Swelling (2nd Bexsero®)0—
Any Induration (2nd Bexsero®)51—
Grade 3 Induration (2nd Bexsero®)0—
Any Tenderness (2nd Bexsero®)67—
Grade 3 Tenderness (2nd Bexsero®)5—
Any Erythema (2nd Infanrix-IPV + Hib®)3912
Grade 3 Erythema(2nd Infanrix-IPV+Hib®)00
Any Swelling (2nd Infanrix-IPV + Hib®)186
Grade 3 Swelling(2nd Infanrix-IPV+Hib®)00
Any Induration (2nd Infanrix-IPV + Hib®)2316
Grade 3Induration(2nd Infanrix-IPV+Hib®)00
Any Tenderness (2nd Infanrix-IPV + Hib®)4510
Grade 3Tenderness(2nd Infanrix-IPV+Hib®)30
Any Erythema (2nd Prevenar-13®)3512
Grade 3 Erythema (2nd Prevenar-13®)00
Any Induration (2nd Prevenar-13®)188
Grade 3 Induration (2nd Prevenar-13®)00
Any Swelling (2nd Prevenar-13®)126
Grade 3 Swelling (2nd Prevenar-13®)00
Any Tenderness (2nd Prevenar-13®)449
Grade 3 Tenderness (2nd Prevenar-13®)30
Any Erythema (3rd Engerix-B®)3312
Grade 3 Erythema (3rd Engerix-B®)00
Any Induration (3rd Engerix-B®)3317
Grade 3 Induration (3rd Engerix-B®)00
Any Swelling (3rd Engerix-B®)256
Grade 3 Swelling (3rd Engerix-B®)00
Any Tenderness (3rd Engerix-B®)457
Grade 3 Tenderness (3rd Engerix-B®)30
Any Erythema (3rd Bexsero®)55—
Grade 3 Erythema (3rd Bexsero®)0—
Any Induration (3rd Bexsero®)57—
Grade 3 Induration (3rd Bexsero®)0—
Any Swelling (3rd Bexsero®)49—
Grade 3 Swelling (3rd Bexsero®)0—
Any Tenderness (3rd Bexsero®)68—
Grade 3 Tenderness (3rd Bexsero®)6—
Any Swelling (3rd Infanrix-IPV+Hib®)2010
Grade 3 Swelling (3rd Infanrix-IPV+Hib®)00
Any Erythema (3rd Infanrix-IPV+Hib®)2815
Grade 3 Erythema (3rd Infanrix-IPV+Hib®)00
Any Induration(3rd Infanrix-IPV+Hib®)2516
Grade 3Induration(3rd Infanrix-IPV+Hib®)00
Any Tenderness (3rd Infanrix-IPV+ Hib®)428
Grade 3Tenderness(3rd Infanrix-IPV+Hib®)20
Any Erythema (3rd Prevenar-13®)2712
Grade 3 Erythema (3rd Prevenar-13®)00
Any Induration (3rd Prevenar-13®)2111
Grade 3 Induration (3rd Prevenar-13®)00
Any Swelling (3rd Prevenar-13®)174
Grade 3 Swelling (3rd Prevenar-13®)00
Any Tenderness (3rd Prevenar-13®)459
Grade 3 Tenderness (3rd Prevenar-13®)30
Any Erythema (4th Bexsero®)53—
Grade 3 Erythema (4th Bexsero®)0—
Any Swelling (4th Bexsero®)44—
Grade 3 Swelling (4th Bexsero®)0—
Any Induration (4th Bexsero®)56—
Grade 3 Induration(4th Bexsero®)0—
Any Tenderness (4th Bexsero®)66—
Grade 3 Tenderness (4th Bexsero®)6—
Any Erythema (4th Priorix®)2413
Grade 3 Erythema (4th Priorix®)00
Any Induration (4th Priorix®)156
Grade 3 Induration (4th Priorix®)00
Any Swelling (4th Priorix®)194
Grade 3 Swelling (4th Priorix®)00
Any Tenderness (4th Priorix®)376
Grade 3 Tenderness (4th Priorix®)30
Any Erythema (4th Varilrix®)3214
Grade 3 Erythema (4th Varilrix®)00
Any Induration (4th Varilrix®)147
Grade 3 Induration (4th Varilrix®)00
Any Swelling (4th Varilrix®)216
Grade 3 Swelling (4th Varilrix®)00
Any Tenderness (4th Varilrix®)415
Grade 3 Tenderness (4th Varilrix®)30
SecondaryNumber of Subjects Reporting Solicited Systemic Adverse Events (AEs) After Receiving Bexsero® Vaccine With Routine Vaccine or Routine Vaccines Alone, at 2, 4, 6 and 12 Months of Age.

Number of subjects reporting solicited systemic AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13® and Engerix-B® at 2, 4 and 6 months of age and Priorix® and Varilrix® at 12 months of age) compared to when only routine vaccines were alone, at 2, 4, 6 and 12 months. Systemic solicited symptoms assessed were Change in Eating Habits, Diarrhea, Irritability, Persistent Crying, Rash, Sleepiness, Vomiting and Fever (body temperature ≥ 38.0 °C)

Time frame:
From day 1 (6 hours) to day 7 after each vaccination
Reported as:
Number · Number of participants
Number of Subjects Reporting Solicited Systemic Adverse Events (AEs) After Receiving Bexsero® Vaccine With Routine Vaccine or Routine Vaccines Alone, at 2, 4, 6 and 12 Months of Age.
Number of participantsBexsero + Routine GroupRoutine Group
Any Change in Eating Habits (1st vacc)9226
Grade3 Change in Eating Habits(1st vacc)00
Any Change in Eating Habits (2nd vacc)7221
Grade3 Change in Eating Habits(2nd vacc)20
Any Change in Eating Habits (3rd vacc)7217
Grade3 Change in Eating Habits(3rd vacc)10
Any Diarrhea (1st vacc)288
Grade 3 Diarrhea (1st vacc)21
Any Diarrhea (2nd vacc)309
Grade 3 Diarrhea (2nd vacc)10
Any Diarrhea (3rd vacc)194
Grade 3 Diarrhea (3rd vacc)00
Any Irritability (1st vacc)11132
Grade 3 Irritability (1st vacc)30
Any Irritability (2nd vacc)9031
Grade 3 Irritability (2nd vacc)50
Any Irritability (3rd vacc)9428
Grade 3 Irritability (3rd vacc)31
Any Persistent Crying (1st vacc)9630
Grade 3 Persistent Crying (1st vacc)50
Any Persistent Crying (2nd vacc)8223
Grade 3 Persistent Crying (2nd vacc)50
Any Persistent Crying (3rd vacc)7228
Grade 3 Persistent Crying (3rd vacc)30
Any Rash (1st vacc)184
Grade 3 Rash (1st vacc)00
Any Rash (2nd vacc)188
Grade 3 Rash (2nd vacc)01
Any Rash (3rd vacc)164
Grade 3 Rash (3rd vacc)10
Any Sleepiness (1st vacc)7933
Grade 3 Sleepiness (1st vacc)01
Any Sleepiness (2nd vacc)6621
Grade 3 Sleepiness (2nd vacc)00
Any Sleepiness (3rd vacc)4913
Grade 3 Sleepiness (3rd vacc)00
Any Vomiting (1st vacc)216
Grade 3 Vomiting (1st vacc)00
Any Vomiting (2nd vacc)169
Grade 3 Vomiting (2nd vacc)00
Any Vomiting (3rd vacc)157
Grade 3 Vomiting (3rd vacc)00
Fever (1st vacc)7111
Fever (2nd vacc)7211
Fever (3rd vacc)6812
Any Change in Eating Habits (4th vacc)5819
Grade3 Change in Eating Habits(4th vacc)21
Any Diarrhea (4th vacc)2710
Grade 3 Diarrhea (4th vacc)10
Any Irritability (4th vacc)7116
Grade 3 Irritability (4th vacc)20
Any Persistent Crying (4th vacc)5815
Grade 3 Persistent Crying (4th vacc)01
Any Rash (4th vacc)259
Grade 3 Rash (4th vacc)10
Any Sleepiness (4th vacc)369
Grade 3 Sleepiness (4th vacc)00
Any Vomiting (4th vacc)106
Grade 3 Vomiting (4th vacc)00
Fever (4th vacc)606
Lymphadenopathy (4th vacc)11
SecondaryNumber of Subjects Reporting Solicited Systemic AEs After Receiving Priorix® and Varilrix® Routine Vaccines (With and Without Bexsero® Vaccine) at 12 Months of Age.

Number of subjects who reported solicited systemic AEs reported after the administration of Varilrix® and Priorix® vaccines (with and without Bexsero® vaccine) at 12 months of age. Solicited systemic AEs assessed were Rash, Lymphadenopathy and Fever. This analysis was conducted for a prolonged period of 28 Days following Varilrix® and Priorix® administration.

Time frame:
From Day 1 to Day 28 after vaccination
Reported as:
Number · Number of participants
Number of Subjects Reporting Solicited Systemic AEs After Receiving Priorix® and Varilrix® Routine Vaccines (With and Without Bexsero® Vaccine) at 12 Months of Age.
Number of participantsBexsero + Routine GroupRoutine Group
Any Rash (4th vacc)5024
Grade 3 rash (4th vacc)55
Lymphadenopathy (4th vacc)3421
Fever (temperature ≥ 38.0°C)9133
Grade 3 fever (temperature ≥ 40.0°C)25
SecondaryNumber of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination With Routine Vaccines

Number of subjects reporting any unsolicited AEs following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B® or Priorix® and Varilrix®) compared to when only routine vaccines were administered alone.

Time frame:
From day 1 to day 7 after each vaccination
Reported as:
Number · Number of subjects
Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination With Routine Vaccines
Number of subjectsBexsero + Routine GroupRoutine Group
Any AEs (1st vacc)468
At least possible related AEs (1st vacc)356
Any AEs (2nd vacc)307
At least possible related AEs (2nd vacc)225
Any AEs (3rd vacc)5118
At least possible related AEs (3rd vacc)457
Any AEs (booster)439
At least possible related AEs (booster)374
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAEs), Medically Attended AEs (MAEs) and AEs Leading to Premature Withdrawal and Death and AEs Leading to Hospitalization.

Number of subjects reporting SAEs, medically attended AEs and AEs leading to premature withdrawal from the study and leading to death and AEs leading to hospitalization following concomitant administration of Bexsero® vaccine with routine vaccines (Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix®) compared to when only routine vaccines were administered alone. SAEs assessed included medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Possibly or probably related SAE were SAEs assessed by the investigator as related to the vaccination. Medically attended AEs were events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason.

Time frame:
Throughout the study period (Day 1 to Day 335)
Reported as:
Number · Number of participants
Number of Subjects Reporting Serious Adverse Events (SAEs), Medically Attended AEs (MAEs) and AEs Leading to Premature Withdrawal and Death and AEs Leading to Hospitalization.
Number of participantsBexsero + Routine GroupRoutine Group
Any SAEs138
At least possible related SAEs00
AEs resulting in premature withdrawal40
AEs leading to hospitalization138
Medically attended AEs13166
AEs leading to death00

Adverse events

Collected over Solicited local AEs and systemic symptoms: from Day 1 to Day 7 after each vaccination; Unsolicited AEs and SAEs: throughout the study period (from Day 1 to Day 335).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bexsero + Routine Group0/148 (0%)13/145 (9%)148/148 (100%)
Routine Group0/73 (0%)8/72 (11.1%)72/73 (98.6%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventBexsero + Routine GroupRoutine Group
Urinary tract infectionInfections and infestations4/1450/72
BronchiolitisInfections and infestations3/1451/72
Kawasaki's diseaseVascular disorders0/1451/72
SeizureNervous system disorders0/1451/72
PyrexiaGeneral disorders1/1451/72
ColitisGastrointestinal disorders0/1451/72
RashSkin and subcutaneous tissue disorders0/1451/72
GastroenteritisInfections and infestations1/1451/72
Otitis media acuteInfections and infestations1/1451/72
PneumoniaInfections and infestations1/1451/72
Most frequent other events
Showing 10 of 27
Most frequent other events
EventBexsero + Routine GroupRoutine Group
PyrexiaGeneral disorders134/14851/73
IrritabilityPsychiatric disorders127/14850/73
Eating disorderPsychiatric disorders125/14843/73
CryingGeneral disorders124/14850/73
Injection site painGeneral disorders121/14827/73
Injection site erythemaGeneral disorders113/14835/73
SomnolenceNervous system disorders111/14845/73
Injection site indurationGeneral disorders105/14839/73
NasopharyngitisInfections and infestations86/14845/73
Injection site swellingGeneral disorders89/14824/73

Baseline characteristics

Age, Continuous
Age, Continuous(Days)Bexsero + Routine GroupRoutine GroupTotal
Mean67.9 ± 6.4668.9 ± 6.8668.3 ± 6.60
Sex: Female, Male
Sex: Female, Male(Participants)Bexsero + Routine GroupRoutine GroupTotal
Female8227109
Male6848116
08

Study locations

2 sites
  • GSK Investigational Site
    Taipei, 10041, Taiwan
  • GSK Investigational Site
    Taipei, 10449, Taiwan
09

References and documents

Publications

  • Chiu NC, Huang LM, Willemsen A, Bhusal C, Arora AK, Reynoso Mojares Z, Toneatto D. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study. Hum Vaccin Immunother. 2018 May 4;14(5):1075-1083. doi: 10.1080/21645515.2018.1425659. Epub 2018 Feb 15. PubMed 29337653 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Dec 2015, 15 months.

Results were first posted in Jun 2018, 2 years 5 months after primary completion. A results delay was requested in Jan 2016.

Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 15 months is close to that.

Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2014
First posted
Jun 25, 2014
StartActual
Sep 11, 2014
Primary completionActual
Dec 25, 2015
CompletionActual
Jun 17, 2016
Results delay requested
Jan 4, 2016
Results first posted
Jun 15, 2018
Last update
Aug 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02173704
Lead sponsor
GlaxoSmithKline
Collaborators
Novartis Vaccines
Responsible party
Sponsor
First posted
Jun 25, 2014
Start date
Sep 11, 2014
Primary completion
Dec 25, 2015
Completion
Jun 17, 2016
Results posted
Jun 15, 2018
Last update
Aug 25, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion